

# Left Ventricular Function and Myocardial Longitudinal Strain Analysis in Patients With Chagas Disease: Case Series and Systematic Literature Review

José Victor da Nóbrega Borges,<sup>1</sup> Samira Abdel Correia Leila,<sup>2</sup> Manuella Guedes da Nóbrega Machado,<sup>3</sup> Kiran Sooraj Thirukonda Jegadeesh Babu,<sup>4</sup> Karma Jashvantbhai Patel,<sup>5</sup> Kavya Hiteshkumar Shah,<sup>5</sup> Mahitha Reddy Takkasila,<sup>6</sup> Abdul Majid Shaik,<sup>7</sup> Muhammad Ahmed Shaikh,<sup>8</sup> Ninad Khandekar,<sup>9</sup> Sahithi Burra<sup>10</sup>

Universidade de São Paulo, Instituto do Coração,<sup>1</sup> São Paulo, SP – Brazil

Hospital Israelita Albert Einstein,<sup>2</sup> São Paulo, SP – Brazil

Clínica Central de Diagnóstico,<sup>3</sup> Vilhena, RO – Brazil

Sri Ramachandra Institute of Higher Education and Research,<sup>4</sup> Sri Ramachandra – India

Gujarat Medical Education and Research Society, Medical College & Hospital Valsad,<sup>5</sup> Valsad, Gujarat – India

Kasturba Medical College Manipal,<sup>6</sup> Manipal, Karnataka – India

Kakatiya Medical College,<sup>7</sup> Warangal, Telangana – India

Jinnah Sindh Medical University,<sup>8</sup> Karachi, Sindh – Pakistan

Government Medical College and Hospital,<sup>9</sup> Thiruvananthapuram, Kerala – India

Osmania Medical College,<sup>10</sup> Hyderabad, Telangana – India

## Abstract

**Introduction:** Left ventricular dysfunction as an independent predictor of mortality in Chagas disease. Global longitudinal strain (GLS) is an emerging echocardiographic modality with possible incremental value in early detection of cardiac involvement.

**Objective:** Compare left ventricular function with multiple echocardiographic parameters between patients with the indeterminate and chronic forms of Chagas, and perform a literature review.

**Methods:** In this observational study, 11 patients with a confirmed diagnosis of Chagas disease were evaluated. Individuals were distributed as follows: five with the indeterminate and six with the chronic forms. Conventional echocardiographic evaluation was followed by GLS measurement.

**Results:** The mean left ventricle ejection fraction left ventricular ejection fraction (LVEF) was  $33 \pm 2.88$ , and the mean GLS of the left ventricle was  $-10.76 \pm 2.20$  in the chronic form as compared to  $57.80 \pm 6.49$  and  $-17.34 \pm 3.82$ , respectively in the indeterminate group. Contractility was reduced in segments of the inferior, inferoseptal and anteroseptal walls in both groups. These segmental alterations in the indeterminate group may be attributed to early myocardial damage from inflammation and fibrosis, even before significant left ventricular dysfunction is evident.

**Conclusion:** Analysis of longitudinal strain in the indeterminate form has potential incremental value to the conventional analysis of ejection fraction when compared to patients with chronic Chagas cardiomyopathy, especially with individual segmental analysis, but the impact and clinical significance of these techniques are still unknown.

**Keywords:** Chagas Cardiomyopathy; Global Longitudinal Strain; Left Ventricular Function.

## Introduction

Chagas disease is one of the leading causes of tropical disease in the New World, with a higher burden than any other parasitic disease in the Americas.<sup>1</sup> It is caused by

infection with *Trypanosoma cruzi* (T. cruzi), a hemoflagellate protozoan parasite primarily transmitted by triatomine bugs, which feed on human and animal blood by biting on exposed areas. From the feces of the bugs, the parasite passes through these breaks in the skin or mucosa causing infection. Rarely, it may be transmitted congenitally via organ transplantation or through contaminated food and water.<sup>2</sup> The different routes of transmission vary between geographic areas. First described in 1909 by Carlos Chagas, after whom it was named, Chagas disease was initially largely confined to Latin America where it is endemic.<sup>3</sup> Though vector transmission has been controlled to an extent in formerly endemic areas, with current migration

**Mailing Address:** José Victor da Nóbrega Borges •  
Instituto de Assistência Médica ao Servidor Público Estadual, Clínica Médica.  
Avenida Ibiapuera, 981. Postal Code: 04084-009. São Paulo, SP – Brazil  
E-mail: josenborges@gmail.com

Manuscript received June 7, 2024; revised July 29, 2024;  
accepted August 18, 2024

Editor responsible for the review: Marcelo Tavares

**DOI:** <https://doi.org/10.36660/abcimg.20240053i>

**Central Illustration: Left Ventricular Function and Myocardial Longitudinal Strain Analysis in Patients With Chagas Disease: Case Series and Systematic Literature Review**



Patient Groups	Indeterminate	Chronic
Mean Age (years)	72.51 ± 5.19	79.56 ± 5.16
LVEF (%)	57.80 ± 6.49	33 ± 2.88
GLS (%)	-17.34 ± 3.82	-10.76 ± 2.20
Segmental Contractility		
Reduced Contractility in Both Groups		
<ul style="list-style-type: none"> <li>- Inferior Wall</li> <li>- Inferoseptal Wall</li> <li>- Anteroseptal Wall</li> </ul>		
Study Summary		
Objective: Compare LV function in indeterminate and chronic forms of Chagas disease, perform a literature review		
Methods: 11 patients, conventional echocardiography, GLS measurement		
Conclusion: GLS offers potential incremental value in early detection of cardiac involvement in Chagas disease.		

Arq Bras Cardiol: Imagem cardiovasc. 2024;37(3):e20240053

LVEF: left ventricular ejection fraction; GLS: Global longitudinal strain; LV: left ventricle.

trends, the prevalence has also increased in the United States, Europe and Japan.<sup>4</sup> In 2019, the global prevalence of Chagas disease was estimated to be 6,469,283, an 11.3% decrease in prevalence in the preceding three decades from 1990. However, it was accompanied by an increase in prevalence in non-endemic countries. Spain had the largest absolute increase in estimated cases, followed by the United States and Italy.<sup>5</sup> This increase is mainly due to the population movement of already-infected individuals from endemic areas in contrast to the rarity of vector-borne transmission in non-endemic countries.<sup>6</sup> Only 16 infections were presumably acquired by autochthonous, vector-borne transmission in the United States from 1955 to 2012.<sup>7,8</sup> Polymerase chain reaction (PCR) testing is the most sensitive test in the diagnosis of acute Chagas infection, including monitoring of the organ transplant patients from *T. cruzi* infected donors and immunocompromised patients.<sup>9</sup> To confirm chronic Chagas disease, at least two serological antibody detection tests with different methods are required.<sup>10,11</sup> Indirect immunofluorescence, enzyme-linked immunosorbent assay (ELISA), and hemagglutination are most commonly used.<sup>12,13</sup> In the acute phase, patients are often asymptomatic or present with mild symptoms such as fever, fatigue, and rash. In contrast, the chronic form usually presents with gastrointestinal manifestations

and, most seriously, cardiomyopathy, including heart failure, arrhythmias, and sudden cardiac death (SCD). Left ventricular dysfunction in an independent predictor of mortality in Chagas disease. Subclinical manifestations often precede systolic dysfunction. In the indeterminate phase, despite the absence of clinical heart disease, myocardial involvement can be detected through imaging modalities. Studies suggest that early inflammatory changes and fibrosis primarily affect the inferoseptal, inferior, and anteroseptal segments, which may explain the segmental contractility alterations observed in our study. Global longitudinal strain (GLS) is a non-invasive modality derived from bidimensional speckle tracking echocardiography (STE).<sup>14</sup> Assessment of STE along with conventional echocardiography has shown to detect subclinical left ventricular myocardial strain abnormalities even before a profound reduction in left ventricular ejection fraction (LVEF) in Chagas cardiomyopathy.<sup>15,16</sup> This technique emerges as a significant predictor of adverse cardiovascular events in patients with the indeterminate form of the disease.<sup>17</sup>

## Methods

A cross-sectional observational study of 11 patients with confirmed diagnosis of Chagas disease was conducted

at a tertiary care specialized hospital in Brazil. Patients underwent detailed history, physical examination, resting electrocardiogram (ECG), and conventional bidimensional echocardiography with Doppler followed by GLS analysis using speckle tracking. Patients were evaluated using echocardiography to assess segmental contractility. Segmental contractility was specifically analyzed in the inferior, inferoseptal, and anteroseptal walls due to their known vulnerability to early myocardial damage in Chagas disease. Previous studies have indicated that inflammation and fibrosis predominantly affect these regions, even in the indeterminate phase. Advanced imaging techniques, such as speckle-tracking echocardiography, have shown these segmental dysfunctions in asymptomatic patients, highlighting the early impact of the disease on the myocardium. Participants had an average age of  $76.36 \pm 6.26$  years, and written informed consent for clinical data usage was required for each individual in the study. The patients were classified as indeterminate (45%) and cardiac (55%) forms of Chagas disease.<sup>18</sup> The patients with Chagas cardiomyopathy were classified as stage B1, B2, C and D.<sup>18</sup> B1 is defined as structural changes as seen on ECG or echocardiography with normal global ventricular function and no symptoms of heart failure. Stage B2 shows structural cardiomyopathy with ventricular dysfunction but no present or past symptoms of heart failure. Stage C is defined as patients with ventricular dysfunction and present or past symptoms of heart failure (all New York Heart Association [NYHA] classes), and stage D is treatment-refractory heart failure requiring specialized interventions. Patients underwent serologic confirmation by anti-T. cruzi enzyme-linked ELISA (Ortho Clinical Diagnostic, USA) and indirect hemagglutination assay (IHA) (Polychaco, Lemos Laboratory SRL, Argentina). Echocardiography was performed using Philips Epiq 7C with a 3.4 MHz sector transducer. Measurements for left ventricular parameters were made according to recommendations by the American Society of Echocardiography and the European Association of Cardiovascular Imaging.<sup>19</sup> LVEF was calculated by the modified Simpson's biplane method using the apical four and two-chamber views. Left ventricle segmental and longitudinal strain analysis were conducted using the QLAB system (Philips, Netherlands). A scoping review of the literature was performed on major medical sciences databases, including Pubmed and Scopus. Keyword inclusion criteria was selected for the following: Chagasic cardiomyopathy and left ventricle GLS. The results were filtered to include full-text case reports of humans with Chagas disease written in English. A total of 25 records were obtained during the initial search. Two reviewers screened the titles and abstracts to determine if they met the inclusion criteria. During the screening, 12 records were excluded. A total of 13 records proceeded to the full-text assessment. Four reviewers assessed the content of the case reports to determine if they had enough information about the patients and their diseases. Baseline characteristics and echocardiographic parameters for the patients enrolled in the study are presented in Table 1.

### Case Series Presentation

This cross-sectional observational study included 11 participants selected from a cohort of Chagas disease patients followed-up at a tertiary center in Brazil, with seven males (63.34%) and four females (36.36%) that were divided into chronic (55%) and indeterminate forms (45%). The mean age of the participants was  $76.36 \pm 6.26$  years, with a mean age of  $79.56 \pm 5.16$  in the chronic group and  $72.51 \pm 5.19$  in the indeterminate group. In terms of classification of disease severity, patients in the chronic and indeterminate phases were classified as B1 and C stages, respectively.<sup>18</sup> Clinical evaluation included detailed history, physical examination, resting ECG, and conventional bidimensional echocardiography with Doppler followed by GLS analysis using speckle tracking. Written consent was obtained from study participants, and even though no direct intervention was promoted, the proposed analysis was also approved by the institutional ethics review board. Patients of the indeterminate form were initially screened and tested for Chagas disease due to either generalized symptoms or suggestive epidemiological history without cardiovascular disease at the time of diagnosis. Patients of the chronic form presented with classic symptoms of heart failure, such as bilateral lower extremity edema, shortness of breath on exertion and paroxysmal nocturnal dyspnea. Three of the six patients (50%) in the chronic form were in NYHA class II, two patients in NYHA class III, and one patient in NYHA class I. One patient of the chronic form also had non-sustained ventricular tachycardia (NSVT) registered on 24-hour Holter monitoring (Figure 1). The mean values for the echocardiographic and baseline parameters for all individuals are presented in Table 2. At the time of diagnosis, serologic confirmation by anti-T. cruzi ELISA (Ortho Clinical Diagnostic, USA) and IHA (Polychaco, Lemos Laboratory SRL, Argentina) were established. All patients were treated according to the most recent guidelines in cardiomyopathies.

Echocardiographic analysis was performed and reviewed by two board-certified echocardiographers using Philips Epiq 7C with a 3.4 MHz sector transducer. Measurements were conducted according to the American Society of Echocardiography and the European Association of Cardiovascular Imaging guidelines.<sup>19</sup> LVEF was calculated by the modified Simpson's biplane method using the apical four and two-chamber views. Left ventricle segmental and longitudinal strain analysis were calculated using the QLAB semi-automatic system (Philips, Netherlands), which considered normal values  $> -18\%$ . The mean values for the echocardiographic parameters divided by groups are presented in Table 3 (chronic form) and Table 4 (indeterminate form). The end-systolic volume and left ventricular systolic diameter of a few patients were not obtained due to technical difficulties and, hence, not included in the data presented.

The mean left ventricle ejection fraction LVEF was  $33 \pm 2.88$ , and the mean GLS of the left ventricle was  $-10.76 \pm 2.20$  in the chronic form as compared to  $57.80 \pm 6.49$  and  $-17.34 \pm 3.82$ , respectively in the indeterminate group. In relation to left ventricle segmental strain, each segment was evaluated individually in each group. Myocardial deformity

**Table 1 – Baseline characteristics and echocardiographic parameters for the patients enrolled in the study**

Patient No.	Age (years)	Body surface area (sq meter)	LVEF (%)	LA volume index (ml sq meter)	LV mass (g)	LV ESV (ml)	LV EDV (ml)	LV GLS (%)	ANTSEPT LS (%)	ANT LS (%)	ANTLAT LS (%)	INFLAT LS (%)	INF LS (%)	INFSEPT LS (%)	E-e' ratio	LVSd (mm)	LVDd (mm)
1	74.5	1.698	31	79.51	277	127	186	-14.2	-9	-18	-20	-19	-15	-17	20.4	51.6	60.8
2	71.58	1.555	28	58.96	185.28	152	195	-7.1	-5	-8	-4	-7	-6	-6	38	55.8	62.2
3	67.66	1.674	51	34.29	377	116	234	-11.2	-16	-11	-10	-11	-11	-6	10	49.5	67.3
4	67.16	1.664	65	40.21	310	53	152	-22.2	-18	-24	-26	-21	-22	-22	13	35.7	55.7
5	78.33	1.73	33	62.41	366		190	-9.8	-9	-8	-10	-11	-11	-6	31.33		61.5
6	83.58	1.791	34	41.2	302		190	-12.1	-14	-11	-14	-20	-8	-8	19.75		61.4
7	77.83	1.492	62	23.13	209	49	149	-18.5	-23	-20	-22	-15	-14	-16	9.8	34.6	55.3
8	85.5	1.528	35	52.28	257	133	204	-9.9	-8	-7	-10	-12	-4	-9	24	52.6	63.4
9	70.33	2.151	49	38.5	287		194	-15.1	-17	-15	-18	-19	-10	-12	13		63
10	79.58	1.932	62	27.33	240		140	-19.7	-13	-27	-19	-18	-21	-19	18		53.7
11	83.91	1.637	37	58.84	381		201	-11.5							65		63

LA: left atrium; LV: left ventricle; LVEF: left ventricle ejection fraction; LV ESV: Left Ventricular End-Systolic Volume; LV EDV: Left Ventricular End-Diastolic Volume; LV GLS: Left Ventricular Global Longitudinal Strain; ANT-SEPT LS: Anterior-Septal Longitudinal Strain; ANT LS: Anterior Longitudinal Strain; ANT-LAT LS: Anterior-Lateral Longitudinal Strain; INF-LAT LS: Inferior-Lateral Longitudinal Strain; INF LS: Inferior Longitudinal Strain; INF-SEPT LS: Inferior-Septal Longitudinal Strain; E-e' ratio: Ratio of early transmitral flow velocity (E) to early diastolic tissue velocity (e') in echocardiography; LVSd: Left Ventricular Septal Diameter; LVDd: Left Ventricular Diastolic Diameter.

analysis by speckle tracking was significantly reduced in all segments of the inferior, inferoseptal and anteroseptal walls in both categories (Figure 2). This finding aligns with literature suggesting that these areas are susceptible to early inflammatory changes and fibrosis in the indeterminate phase of Chagas disease, which can occur before significant left ventricular dysfunction manifests. Previous studies have identified these segmental abnormalities as early indicators of myocardial damage, even in the absence of overt clinical symptoms.<sup>17,18</sup>

## Discussion

Chagas disease cardiac involvement presents most commonly in the form of dilated cardiomyopathy as a result of chronic inflammation with subsequent cardiomyocyte loss. The final stage of the disease is characterized by the disruption of muscle fibers and neuronal structures with replacement by fibrotic tissue. This architectural anomaly contributes to electrophysiological dysfunction and is a major factor in the propensity of chagasic individuals to experience ventricular arrhythmias and heart failure,<sup>18,20,21</sup> accounting for considerable morbidity and mortality.<sup>15</sup> The degree of ventricular dysfunction also determines the severity of ventricular arrhythmia. One of the main causes of death in this population is SCD, accounting for nearly 55-60% of deaths. Patients with a history of syncope, severe bradyarrhythmia, and cardiac arrest are more likely to develop SCD.<sup>18,21,22</sup> Clinical features can be divided into three stages: acute, indeterminate, and chronic. Acute Chagas disease typically persists from 8 to 12 weeks. It frequently remains undiagnosed because most patients are asymptomatic or

experience only mild and nonspecific symptoms such as fever, tiredness, lymphadenopathy, hepatomegaly, and splenomegaly. Local signs at the infection site may also be noted, like the characteristic chagoma (T. cruzi skin abscess) or the Romaña sign (unilateral conjunctivitis with painless swelling of the eyelids). Other organ systems less frequently involved include the gastrointestinal tract and nervous system. The fulminant disease commonly presents with acute myocarditis, pericardial effusion, and mural thrombosis.<sup>18</sup> In the indeterminate phase, patients are asymptomatic and have preserved LVEF. Nearly 20-40% of patients with acute Chagas disease<sup>23</sup> develop the chronic disease 20 to 30 years later, either in the form of megaesophagus, megacolon or Chagas Heart disease.<sup>24</sup> Cardiac involvement is marked by significant arrhythmias (both supraventricular or ventricular) and ventricular aneurysms.<sup>25</sup> Damage to the electrical conduction system is also a prevalent cause of atrioventricular block,<sup>15</sup> with right bundle branch block (RBBB) as the most common intraventricular conduction abnormality and often one of the first manifestations of the disease. The combination of RBBB and left anterior fascicular block is strongly suggestive of Chagas disease<sup>18</sup> in high-risk groups. Pulmonary and systemic thromboembolism formation,<sup>26</sup> myocardial scarring and wall motion abnormalities, most commonly in the apical and inferolateral walls, are also reported. Cardiac manifestations make up a significant part of Chagas disease morbidity and mortality, but clinical deterioration can have an insidious course, as seen in the indeterminate form. We intend to compare the progression of left ventricular function through multiple echocardiographic parameters in indeterminate and chronic forms of Chagas disease through a case series. In doing so, we suggested the possibility of using




Figure 1 – Documentation of NSVT on 24-hour Holter monitoring for one of the patients with the chronic form of the disease.

Table 2 – Mean values of all participants

Variable	Value
N	11
Male (%)	63.64
Female (%)	36.36
Age (years)	76.36 ± 6.26
Body surface area (sq meter)	1.7138 ± 0.1819
LVEF (%)	44.27 ± 13.27
LA volume index (ml sq meter)	46.96 ± 16.16
LV mass (g)	290.11 ± 62.85
LVSD (mm)	46.63 ± 9.13
LVDd (mm)	60.66 ± 3.90
LV ESV (ml)	105 ± 43.44
LV EDV (ml)	185 ± 26.38
E-e' ratio	23.84 ± 15.48
ANT-SEPT LS (%)	-13.20 ± 5.21
ANT LS	-14.90 ± 6.72
ANT-LAT LS (%)	-15.30 ± 6.45
INF-LAT LS (%)	-14.63 ± 5.04
INF LS	-12.20 ± 5.61
INF-SEPT LS (%)	-12.10 ± 5.68
LV GLS (%)	-13.75 ± 4.47

LA: left atrium; LV: left ventricle; LVEF: left ventricle ejection fraction; LVSD: Left Ventricular Septal Diameter; LVDd: Left Ventricular Diastolic Diameter; LV ESV: Left Ventricular End-Systolic Volume; LV EDV: Left Ventricular End-Diastolic Volume; ANT-SEPT LS: Anterior-Septal Longitudinal Strain; LV GLS: Left Ventricular Global Longitudinal Strain; INF-SEPT LS: Inferior-Septal Longitudinal Strain; INF LS: Inferior Longitudinal Strain; INF-LAT LS: Inferior-Lateral Longitudinal Strain; ANT-LAT LS: Anterior-Lateral Longitudinal Strain; ANT LS: Anterior Longitudinal Strain; E-e' ratio: Ratio of early transmitral flow velocity (E) to early diastolic tissue velocity (e') in echocardiography.

Table 3 – Mean values of participants with chronic form

Variable	Value
N	6
Age	79.56 ± 5.18
Body surface area (sq meter)	1.6565 ± 0.1024
LVEF (0/0)	33 ± 2.88
LA volume index (ml sq meter)	58.87 ± 12.60
LV mass (g)	294.71 ± 72.51
LVSD (mm)	53.33 ± 2.19
LVDd (mm)	62.05 ± 1.00
LV ESV (ml)	137.33 ± 13.05
LV EDV (ml)	194.33 ± 7.005
E-e' ratio	33.08 ± 17.13
ANT-SEPT LS	-9.83 ± 3.54
ANT LS	-10.83 ± 4.16
ANT-LAT LS	-11.16 ± 5.38
INF-LAT LS (%)	-12.83 ± 5.49
INF LS (%)	-8.33 ± 4.03
INF-SEPT LS	-8.83 ± 4.16
LV GLS (%)	10.76 ± 2.20


LA: left atrium; LV: left ventricle; LVEF: left ventricle ejection fraction; LV ESV: Left Ventricular End-Systolic Volume; LV EDV: Left Ventricular End-Diastolic Volume; LV GLS: Left Ventricular Global Longitudinal Strain; ANT-SEPT LS: Anterior-Septal Longitudinal Strain; ANT LS: Anterior Longitudinal Strain; ANT-LAT LS: Anterior-Lateral Longitudinal Strain; INF-LAT LS: Inferior-Lateral Longitudinal Strain; INF LS: Inferior Longitudinal Strain; INF-SEPT LS: Inferior-Septal Longitudinal Strain; E-e' ratio: Ratio of early transmitral flow velocity (E) to early diastolic tissue velocity (e') in echocardiography; LVSD: Left Ventricular Septal Diameter; LVDd: Left Ventricular Diastolic Diameter.

**Table 4 – Mean values of participants with indeterminate form.**

Variable	Value
N	5
Age	72.51 ± 5.19
Body surface area (sq meter)	1.7826 ± 0.26
LVEF (0/0)	57.80 ± 6.49
LA volume index (ml sq meter)	32.69 ± 7.29
LV mass (g)	284.6 ± 64.98
LVSD (mm)	39.93 ± 8.30
LVDd (mm)	59 ± 5.86
LV ESV (ml)	72.67 ± 37.58
LV EDV (ml)	173.8 ± 39.57
E-e' ratio	12.76 ± 3.31
ANT-SEPT LS	-17.4 ± 3.65
ANT LS	-19.4 ± 6.50
ANT-LAT LS	-19 ± 5.92
INF-LAT LS (%)	-16.8 ± 3.89
INF LS (%)	-15.6 ± 5.59
INF-SEPT LS	-15 ± 6.24
LV GLS (%)	17.34 ± 3.82

LA: left atrium; LV: left ventricle; LVEF: left ventricle ejection fraction; LV ESV: Left Ventricular End-Systolic Volume; LV EDV: Left Ventricular End-Diastolic Volume; LV GLS: Left Ventricular Global Longitudinal Strain; ANT-SEPT LS: Anterior-Septal Longitudinal Strain; ANT LS: Anterior Longitudinal Strain; ANT-LAT LS: Anterior-Lateral Longitudinal Strain; INF-LAT LS: Inferior-Lateral Longitudinal Strain; INF LS: Inferior Longitudinal Strain; INF-SEPT LS: Inferior-Septal Longitudinal Strain; E-e' ratio: Ratio of early transmitral flow velocity (E) to early diastolic tissue velocity (e') in echocardiography; LVSD: Left Ventricular Septal Diameter; LVDd: Left Ventricular Diastolic Diameter.

GLS as an incremental value to the ejection fraction of the left ventricle in the early identification of cardiac changes. In the indeterminate group, these segmental contractility alterations are particularly noteworthy. Early myocardial damage characterized by inflammation and fibrosis, often localized in the inferior, inferoseptal, and anteroseptal walls, has been documented in patients with indeterminate Chagas disease. This supports our observation of contractility changes in these segments, underscoring the need for vigilant cardiac monitoring even in asymptomatic patients. The pathophysiological basis for these changes involves an ongoing inflammatory response, with subsequent fibrosis, which disrupts normal myocardial function, particularly in these vulnerable regions.<sup>15,21</sup> Concurrently, a literature review of the topic was also conducted. The analysis of left ventricular myocardial changes in Chagas cardiomyopathy using speckle tracking was first studied across the spectrum of ejection fractions (from preserved to reduced) by Lima et al.<sup>27</sup> Speckle tracking is an echocardiographic tool that allows automated



**Figure 2 –** As represented in the bull's eye, segmental contractility of the left ventricle analyzed by bidimensional strain derived from STE was significantly reduced in the inferior, inferoseptal, and anteroseptal walls, with similar results in both groups. ANT-SEPT: Anterior-Septal; ANT: Anterior; ANT-LAT: Anterior-Lateral; INF-LAT: Inferior-Lateral; INF: Inferior; INF-SEPT: Inferior-Septal

quantitative frame-by-frame tracking of interactions between acoustic changes and regional myocardial changes.<sup>27,28</sup> The study showed a decreased strain in the inferior and posterior heart walls with a paradoxical increase in septal and anterior segments across the evolution of Chagas cardiomyopathy. It also demonstrated reduced longitudinal velocities in the indeterminate form.<sup>27</sup> Another cross-sectional study was able to demonstrate an early abnormal change in regional longitudinal strain in patients with indeterminate form localized to the inferior, septal inferior and inferolateral segments. When compared with cardiac magnetic resonance imaging, these changes occurred before cardiac fibrosis.<sup>29</sup> The prognostic value of biomarkers and strain parameters has been prospectively studied more recently in the same cohort that demonstrated an independent association of LV GLS, left ventricular torsion and brain natriuretic peptide (BNP) levels with a composite outcome consisting of mortality, hospital admission, heart transplant or device implantation in patients with chronic Chagas disease.<sup>30</sup> In our review, we have included the study data on STE in Chagas disease currently present in literature (Table 5). The general concept and summary of this case series and literature review are presented in the central figure.

## Conclusion

Our study highlights the importance of early detection and management of myocardial involvement in Chagas disease. The addition of GLS analysis to conventional echocardiography yields a potential incremental value at the detection of subclinical myocardial changes before a significant reduction in left ventricle ejection fraction. The segmental contractility alterations observed in the

**Table 5 – Data on STE in Chagas disease currently present in literature**

Author	Type of Study	Participants	Parameters
García-Alvaraez et al. (2011) <sup>31</sup>	Cross-sectional	98	GLS, radial and circumferential strain
Barbosa et al. (2014) <sup>32</sup>	Cross-sectional	78	GLS, radial and circumferential strain
Gomes et al. (2016) <sup>33</sup>	Cross-sectional	126	GLS, radial and circumferential strain
Lima et al. (2016) <sup>27</sup>	Cross-sectional	131	GLS, twist/torsion and rotational strain
Lima et al. (2017) <sup>34</sup>	Cross-sectional	42	GLS, twist/torsion and rotational strain
Santos Jr. et al. (2019) <sup>35</sup>	Prospective cohort	122	GLS
Echeverría et al. (2020) <sup>36</sup>	Cross-sectional	273	GLS
Cianciulli et al. (2021) <sup>28</sup>	Cross-sectional	90	GLS
Romano et al. (2020) <sup>29</sup>	Cross-sectional	69	GLS, radial and circumferential strain
Echeverría et al. (2022) <sup>17</sup>	Prospective cohort	177	GLS
Win et al. (2022) <sup>15</sup>	Prospective cohort	139	GLS
Hotta et al. (2022) <sup>23</sup>	Prospective cohort	72	GLS
Mendes et al. (2023) <sup>30</sup>	Prospective cohort	361	GLS

GLS: Global longitudinal strain.

indeterminate group emphasize the significance of recognizing early myocardial damage. Targeted imaging and timely interventions are crucial to managing these patients effectively and preventing progression to symptomatic heart disease. When compared to patients with the chronic variant of Chagas disease, individual segmental analysis in the indeterminate form may allow early recognition of patients at risk for progression to clinical cardiac dysfunction as suggested by this case series and systematic literature review in line with currently available data. Our findings are consistent with existing literature that highlights the subclinical myocardial involvement in the indeterminate phase of Chagas disease, which necessitates proactive cardiac evaluation and management strategies to mitigate long-term complications. However, the clinical impact and significance of these newer techniques remain unknown.

### Author Contributions

Conception and design of the research: Borges JVN, Leila SAC, Machado MGN; acquisition of data: Borges JVN, Machado MGN; analysis and interpretation of the data: Borges JVN, Babu KSTJ, Shaik AM, Burra S, Takkasila MR, Patel KJ, Shah KH; statistical analysis: Leila SAC, Machado MGN, Babu KSTJ, Shaik AM, Takkasila MR, Patel KJ, Shah KH, Shaikh MA;

writing of the manuscript: Borges JVN, Leila SAC, Babu KSTJ, Shaik AM, Burra S, Takkasila MR, Patel KJ, Shah KH, Shaikh MA; critical revision of the manuscript for intellectual content: Borges JVN, Leila SAC, Machado MGN, Burra S, Shaikh MA.

### Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported

### Sources of Funding

There were no external funding sources for this study.

### Study Association

This study is not associated with any thesis or dissertation work.

### Ethics Approval and Consent to Participate

This study was approved by the Ethics Committee of the Comitê de Ética da Central de Diagnóstico e Pesquisa Clínica under the protocol number 01.2023/579831. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.

### References

- World Health Organization. Global Burden of Disease Estimates: 2004 Update. Geneva: WHO; 2008.
- Fuentes-Vicente JA, Gutiérrez-Cabrera AE, Flores-Villegas AL, Lowenberger C, Benelli G, Salazar-Schettino PM, et al. What Makes an Effective Chagas Disease
- Vector? Factors Underlying Trypanosoma Cruzi-triatomine Interactions. Acta Trop. 2018;183:23-31. doi: 10.1016/j.actatropica.2018.04.008.
- Chagas C. Nova Tripanozomíaze Humana: Estudos sobre a Morfologia e o Ciclo Evolutivo do Schizotrypanum Cruzi n. gen., n. sp., Ajente

- Etiológico de Nova Entidade Morbida do Homem. Mem Inst Oswaldo Cruz. 1909;1:159-218. doi: 10.1590/S0074-02761909000200008.
4. Dias JC, Silveira AC, Schofield CJ. The Impact of Chagas Disease Control in Latin America: A Review. Mem Inst Oswaldo Cruz. 2002;97(5):603-12. doi: 10.1590/s0074-02762002000500002.
  5. Gómez-Ochoa SA, Rojas LZ, Echeverría LE, Muka T, Franco OH. Global, Regional, and National Trends of Chagas Disease from 1990 to 2019: Comprehensive Analysis of the Global Burden of Disease Study. Glob Heart. 2022;17(1):59. doi: 10.5334/gh.1150.
  6. Gascon J, Bern C, Pinazo MJ. Chagas Disease in Spain, the United States and Other Non-endemic Countries. Acta Trop. 2010;115(1-2):22-7. doi: 10.1016/j.actatropica.2009.07.019.
  7. Dorn PL, Perniciaro L, Yabsley MJ, Roellig DM, Balsamo G, Diaz J, et al. Autochthonous Transmission of Trypanosoma Cruzi, Louisiana. Emerg Infect Dis. 2007;13(4):605-7. doi: 10.3201/eid1304.061002.
  8. Cantey PT, Stramer SL, Townsend RL, Kamel H, Ofafa K, Todd CW, et al. The United States Trypanosoma Cruzi Infection Study: Evidence for Vector-borne Transmission of the Parasite that Causes Chagas Disease Among United States Blood Donors. Transfusion. 2012;52(9):1922-30. doi: 10.1111/j.1537-2995.2012.03581.x.
  9. Chin-Hong PV, Schwartz BS, Bern C, Montgomery SP, Kontak S, Kubak B, et al. Screening and Treatment of Chagas Disease in Organ Transplant Recipients in the United States: Recommendations from the Chagas in Transplant Working Group. Am J Transplant. 2011;11(4):672-80. doi: 10.1111/j.1600-6143.2011.03444.x.
  10. Schijman AG, Vigliano C, Burgos J, Favaloro R, Perrone S, Laguens R, et al. Early Diagnosis of Recurrence of Trypanosoma Cruzi Infection by Polymerase Chain Reaction after Heart Transplantation of a Chronic Chagas' Heart Disease Patient. J Heart Lung Transplant. 2000;19(11):1114-7. doi: 10.1016/s1053-2498(00)00168-6.
  11. Gomes ML, Galvao LM, Macedo AM, Pena SD, Chiari E. Chagas' Disease Diagnosis: Comparative Analysis of Parasitologic, Molecular, and Serologic Methods. Am J Trop Med Hyg. 1999;60(2):205-10. doi: 10.4269/ajtmh.1999.60.205.
  12. Bern C, Montgomery SP, Herwaldt BL, Rassi AJr, Marin-Neto JA, Dantas RO, et al. Evaluation and Treatment of Chagas Disease in the United States: A Systematic Review. JAMA. 2007;298(18):2171-81. doi: 10.1001/jama.298.18.2171.
  13. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Brazilian Consensus on Chagas Disease. Rev Soc Bras Med Trop. 2005;38(Suppl 3):7-29.
  14. Kang Y, Xu X, Cheng L, Li L, Sun M, Chen H, et al. Two-dimensional Speckle Tracking Echocardiography Combined with High-sensitive Cardiac Troponin T in Early Detection and Prediction of Cardiotoxicity During Epirubicin-based Chemotherapy. Eur J Heart Fail. 2014;16(3):300-8. doi: 10.1002/ejhf.8.
  15. Win S, Miranda-Schaebinger M, Saucedo RGD, Jimenez PC, Flores J, Mercado-Saavedra B, et al. Early Identification of Patients with Chagas Disease at Risk of Developing Cardiomyopathy Using 2-D Speckle Tracking Strain: Win, Miranda Prediction of Chagas Cardiomyopathy. Int J Cardiol Heart Vasc. 2022;41:101060. doi: 10.1016/j.ijcha.2022.101060.
  16. Collier P, Phelan D, Klein A. A Test in Context: Myocardial Strain Measured by Speckle-tracking Echocardiography. J Am Coll Cardiol. 2017;69(8):1043-56. doi: 10.1016/j.jacc.2016.12.012.
  17. Echeverría LE, Rojas LZ, Rueda-Ochoa OL, Gómez-Ochoa SA, Mayer MA, Becerra-Motta LP, et al. Longitudinal Strain by Speckle Tracking and Echocardiographic Parameters as Predictors of Adverse Cardiovascular Outcomes in Chronic Chagas Cardiomyopathy. Int J Cardiovasc Imaging. 2022;38(6):1245-55. doi: 10.1007/s10554-021-02508-5.
  18. Nunes MCP, Beaton A, Acquatella H, Bern C, Bolger AF, Echeverría LE, et al. Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement from the American Heart Association. Circulation. 2018;138(12):169-209. doi: 10.1161/CIR.0000000000000599.
  19. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. doi: 10.1016/j.echo.2014.10.003.
  20. Rocha MO, Ribeiro ALP, Teixeira MM. Clinical Management of Chronic Chagas Cardiomyopathy. Front Biosci. 2003;8:e44-54. doi: 10.2741/926.
  21. Andrade JP, Marin-Neto JA, Paola AA, Vilas-Boas F, Oliveira GM, Bacal F, et al. I Latin American Guidelines for the Diagnosis and Treatment of Chagas' Heart Disease: Executive Summary. Arq Bras Cardiol. 2011;96(6):434-42. doi: 10.1590/s0066-782x2011000600002.
  22. Rassi AJr, Rassi SG, Rassi A. Sudden Death in Chagas' Disease. Arq Bras Cardiol. 2001;76(1):75-96. doi: 10.1590/s0066-782x2001000100008.
  23. Hotta VT, Abduch MCD, Vieira MLC, Vilela AA, Bocchi EA. Three and Two-dimensional Cardiac Mechanics by Speckle Tracking are Predictors of Outcomes in Chagas Heart Disease. Sci Rep. 2022;12(1):12237. doi: 10.1038/s41598-022-16379-w.
  24. Rassi A Jr, Rassi A, Little WC. Chagas' Heart Disease. Clin Cardiol. 2000;23(12):883-9. doi: 10.1002/clc.4960231205.
  25. Ribeiro FFF, Moreira HT, Barros-Filho ACL, Tanaka DM, Fabricio CG, Oliveira LFL, et al. Prospective Analysis of Myocardial Strain Through the Evolution of Chagas Disease in the Hamster Animal Model. Int J Cardiovasc Imaging. 2022;38(1):117-29. doi: 10.1007/s10554-021-02379-w.
  26. Choudhuri S, Garg NJ. Platelets, Macrophages, and Thromboinflammation in Chagas Disease. J Inflamm Res. 2022;15:5689-706. doi: 10.2147/JIR.S380896.
  27. Lima MS, Villarraga HR, Abduch MC, Lima MF, Cruz CB, Bittencourt MS, et al. Comprehensive Left Ventricular Mechanics Analysis by Speckle Tracking Echocardiography in Chagas Disease. Cardiovasc Ultrasound. 2016;14(1):20. doi: 10.1186/s12947-016-0062-7.
  28. Cianciulli TF, Albarracín GA, Llobera MN, Prado NG, Saccheri MC, Vásquez YMH, et al. Speckle Tracking Echocardiography in the Indeterminate Form of Chagas Disease. Echocardiography. 2021;38(1):39-46. doi: 10.1111/echo.14917.
  29. Romano MMD, Moreira HT, Marin-Neto JA, Baccelli PE, Alenezi F, Klem I, et al. Early Impairment of Myocardial Deformation Assessed by Regional Speckle-tracking Echocardiography in the Indeterminate Form of Chagas Disease without Fibrosis Detected by Cardiac Magnetic Resonance. PLoS Negl Trop Dis. 2020;14(11):e0008795. doi: 10.1371/journal.pntd.0008795.
  30. Mendes VG, Rimolo L, Lima ACB, Ferreira RR, Oliveira LS, Nisimura LM, et al. Biomarkers and Echocardiographic Predictors of Cardiovascular Outcome in Patients with Chronic Chagas Disease. J Am Heart Assoc. 2023;12(12):e028810. doi: 10.1161/JAHA.122.028810.
  31. García-Álvarez A, Sitges M, Regueiro A, Poyatos S, Pinazo MJ, Posada E, et al. Myocardial Deformation Analysis in Chagas Heart Disease with the Use of Speckle Tracking Echocardiography. J Card Fail. 2011;17(12):1028-34. doi: 10.1016/j.cardfail.2011.08.007.
  32. Barbosa MM, Rocha MOC, Vidigal DF, Carneiro RCB, Araújo RD, Palma MC, et al. Early Detection of Left Ventricular Contractility Abnormalities by Two-dimensional Speckle Tracking Strain in Chagas' Disease. Echocardiography. 2014;31(5):623-30. doi: 10.1111/echo.12426.
  33. Gomes VA, Alves GF, Hadlich M, Azevedo CF, Pereira IM, Santos CR, et al. Analysis of Regional Left Ventricular Strain in Patients with Chagas Disease and Normal Left Ventricular Systolic Function. J Am Soc Echocardiogr. 2016;29(7):679-88. doi: 10.1016/j.echo.2016.03.007.

34. Lima MS, Voos MC, Mathias W Jr, Tsutsui JM. Indeterminate form of Chagas Disease: Is Left Ventricular Torsional Mechanics a Clue to Subclinical Myocardial Abnormalities? *J Echocardiogr*. 2017;15(1):6-12. doi: 10.1007/s12574-016-0305-5.
35. Santos OR Jr, Rocha MOC, Almeida FR, Cunha PFS, Souza SCS, Saad GP, et al. Speckle Tracking Echocardiographic Deformation Indices in Chagas and Idiopathic Dilated Cardiomyopathy: Incremental Prognostic Value of Longitudinal Strain. *PLoS One*. 2019;14(8):e0221028. doi: 10.1371/journal.pone.0221028.
36. Echeverría LE, Rojas LZ, Villamizar MC, Luengas C, Chaves AM, Rodríguez JA, et al. Echocardiographic Parameters, Speckle Tracking, and Brain Natriuretic Peptide Levels as Indicators of Progression of Indeterminate Stage to Chagas Cardiomyopathy. *Echocardiography*. 2020;37(3):429-38. doi: 10.1111/echo.14603.



This is an open-access article distributed under the terms of the Creative Commons Attribution License